OBJECTIVE: To systematically evaluate the clinical efficacy of Xuezhikang capsules combined with statins in the treatment of hyperlipidemia.METHODS: PubMed

the Cochrane Library

CNKI

Wanfang database and VIP database were retrieved to collect the randomized controlled trial（ RCT） of Xuezhikang capsules combined with statins in the treatment of hyperlipidemia（ the study group was given Xuezhikang capsules combined with statins

while the control group received statins）.The retrieval time was from the establishment of the database to Dec.2020.Newcastle-Ottawa scale（ NOS） was used to evaluate the quality of the literature.Parameters of triglyceride（ TG）

total cholesterol（ TC）

high density lipoprotein cholesterol（ HDL-C） and low density lipoprotein cholesterol（ LDL-C）were extracted.RevMan5.3 software was used for Meta-analysis

sensitivity analysis and publication bias detection.RESULTS: A total of 11 literature that met the criteria were included

with a total of 1 559 cases

including 782 cases in the study group and 777 cases in the control group.Adverse drug reactions were mentioned in 6 literature.Metaanalysis showed that the total effective rate of the study group was significantly higher than that of the control group（ OR = 3.60

95%CI= 2.56-5.07

Z = 7.33

P

<

0.000 01

I

2

= 0%

<

50%）

the levels of TC（ MD =-0.58

95% CI =-0.66--0.50

Z = 14.23

P

<

0.000 01

I

2

= 49%

<

50%）

TG（ MD =-0.24

95% CI =-0.28--0.20

Z = 11.39

P

<

0.000 01

I

2

= 46%

<

50%） and LDL-C（ MD =-0.40

95% CI =-0.45--0.35

Z = 14.54

P

<

0.000 01

I

2

= 48%

<

50%） and other indicators were significantly lower than those of the control group

the level of HDL-C was significantly higher than that of the control group（ MD = 0.23

95%CI = 0.20-0.26

Z = 16.13

P

<

0.000 01

I

2

= 44%

<

50%）

and the incidence of adverse drug reactions was significantly lower than that of the control group（ OR = 0.41

95%CI = 0.19-0.91

Z = 2.19

P

<

0.03

I

2

= 5%

<

50%）

with statistically significant differences.CONCLUSIONS:Xuezhikang capsules combined with statins in the treatment of hyperlipidemia has better comprehensive efficacy and lower incidence of adverse drug reactions than statins alone

and its effects in reducing TG

TC

LDL-C and increasing HDL-C are significantly better than that of statins alone.